Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Bullboard Posts
Post by alixx11on Dec 31, 2009 12:38pm
333 Views
Post# 16629490

Niogold private placement

Niogold private placement

Niogold Mining 8.09-million-share private placement

2009-12-30   20:12 ET - Private Placement

TheTSX Venture Exchange has accepted for filing documentation with respectto a non-brokered private placement announced Dec. 7, 2009.

Number of shares:  2.69 million flow-through shares and5.4 million non-flow-through shares

Purchase price:  30 cents per flow-through share and 25 cents per non-flow-through share

Warrants:  4,045,000 share purchase warrants to purchase 4,045,000 shares

Warrant exercise price:  50 cents for a one-year period and 75 cents inthe second year (If the company's shares close at 75 cents or greaterfor a period of 10 consecutive trading days during the first year or $1or greater for a period of 10 consecutive trading days during thesecond year, the company may, upon notice to the warrantholders,accelerate the expiry date so that the warrants will expire on not lessthan 30 days after such notice.)

Hidden placees:  58 hidden placees

Insider:  Toby Lim, 40,000 flow-through shares

Pro group:  Thomas Seltzer, 80,000 non-flow-through shares

Finders' fees:  First Canadian Capital Markets Ltd. receives $43,400and 172,800 non-transferrable warrants, each exercisable for one shareat a price of 25 cents per share for a two-year period; Leede FinancialMarkets Inc. receives $12,800 and 45,333 non-transferrable warrants,each exercisable for one share at a price of 25 cents per share for atwo-year period; Canaccord Capital Corp. receives $55,616 and 207,850non-transferrable warrants, each exercisable for one share at a priceof 25 cents per share for a two-year period; Axemen Resource CapitalLtd. receives 96,000 shares and 80,000 non-transferrable warrants, eachexercisable for one share at a price of 25 cents per share for atwo-year period

Bullboard Posts